Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.

Chief Executive Officer Michael Metzger said the company’s two marketed medicines generated a combined $115 million in second-quarter net sales.

Revuforj recorded $54.7 million in net revenue, while Niktimvo generated $60 million in net sales reported by Syndax’s partner Incyte.

Syndax recognized $18.1 million in Niktimvo collaboration revenue, representing 30% of the therapy’s reported net revenue.

Revuforj net revenue rose 91% year over year and 12% sequentially to $55 million.

Total prescriptions increased 15% from the first quarter to approximately 1,500, according to Chief Commercial Officer Steve Closter.

The medicine has treated more than 1,600 commercial patients since launch, including 250 new patients in the second quarter.

Closter said Syndax saw some quarter-to-quarter fluctuation in new patient starts, which he attributed to the variability inherent in rare diseases, clinical-trial activity and physician treatment choices when more than one therapy may be considered based on a patient’s mutation profile.

Still, company executives emphasized that growing treatment duration is becoming an increasingly important contributor to Revuforj revenue.

Syndax said approximately 50% of KMT2A patients receiving Revuforj proceed to stem-cell transplant.

Of those patients, about 50% have resumed therapy after a three- to six-month pause, compared with an estimated 45% in the previous quarter.

Closter said Syndax expects 70% to 80% of transplant patients may eventually resume therapy for one to two years, based on physician feedback and clinical and real-world experience.

Patients who have resumed treatment after transplant are averaging at least nine months on therapy, while patients who do not undergo transplant are averaging more than seven months of treatment.

Revuforj’s use in NPM1-mutated acute myeloid leukemia is also expanding.

NPM1 accounted for at least 40% of new patients in the second quarter and more than 30% of Revuforj net revenue.

Syndax estimates that fewer than 15% of the approximately 4,500 annual relapsed or refractory NPM1 patients have received a menin inhibitor, leaving room for further market penetration.

More than 580 accounts had ordered Revuforj, up 11% sequentially.

Nearly 90% of the company’s Tier 1 and Tier 2 accounts had ordered the drug, compared with 70% before the NPM1 approval.

Revuforj had formulary coverage for 98% of covered lives across both indications at the end of the quarter.

Claims data showed that 75% of Revuforj use was in second- and third-line treatment, with about 40% of use in combination regimens.

Metzger said Syndax now expects Revuforj could generate more than $2 billion in peak annual U.S. ...